Lubaba, A., & Fariha, L. M. (2024). PCSK9i: Proprotein convertase subtilisin/kexin type 9 inhibitor a new phase of lipid-lowering treatment. Brac University.
Cita Chicago Style (17a ed.)Lubaba, Anikah, y Luluel Maknun Fariha. PCSK9i: Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor a New Phase of Lipid-lowering Treatment. Brac University, 2024.
Cita MLA (8a ed.)Lubaba, Anikah, y Luluel Maknun Fariha. PCSK9i: Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor a New Phase of Lipid-lowering Treatment. Brac University, 2024.
Precaución: Estas citas no son 100% exactas.